EP2302386A1 - Membrane à transfert de protéines hydrophile, à liaison à protéines, à faible fluorescence - Google Patents

Membrane à transfert de protéines hydrophile, à liaison à protéines, à faible fluorescence Download PDF

Info

Publication number
EP2302386A1
EP2302386A1 EP10190559A EP10190559A EP2302386A1 EP 2302386 A1 EP2302386 A1 EP 2302386A1 EP 10190559 A EP10190559 A EP 10190559A EP 10190559 A EP10190559 A EP 10190559A EP 2302386 A1 EP2302386 A1 EP 2302386A1
Authority
EP
European Patent Office
Prior art keywords
membrane
substrate
acrylamide
hydrophilic
avail
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10190559A
Other languages
German (de)
English (en)
Other versions
EP2302386B1 (fr
Inventor
Antoni Peters
Philip Goddard
John Charkoudian
Neil Soice
Dave Brewster
Anja Dedeo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EMD Millipore Corp
Original Assignee
Millipore Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millipore Corp filed Critical Millipore Corp
Publication of EP2302386A1 publication Critical patent/EP2302386A1/fr
Application granted granted Critical
Publication of EP2302386B1 publication Critical patent/EP2302386B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
    • B01D67/0081—After-treatment of organic or inorganic membranes
    • B01D67/0093—Chemical modification
    • B01D67/00933—Chemical modification by addition of a layer chemically bonded to the membrane
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2323/00—Details relating to membrane preparation
    • B01D2323/02—Hydrophilization
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2323/00—Details relating to membrane preparation
    • B01D2323/30—Cross-linking
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2325/00—Details relating to properties of membranes
    • B01D2325/36—Hydrophilic membranes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Definitions

  • “Blotting” or “electro-blotting” refers to the process used to transfer biological samples from a gel to a membrane under the influence of an electric field. The process requires a membrane that can immobilize biomolecular samples for subsequent detection. This places specific requirements on the membranes related to surface area, porosity, and protein binding capacity.
  • Western blotting is one modification of this technique that involves the immobilization of proteins on membranes before detection using monoclonal or polyclonal antibodies.
  • sample proteins Prior to protein immobilization on the membrane, sample proteins are separated using SDS polyacrylamide gel electrophoresis (SDS-PAGE) to separate native or denatured proteins.
  • SDS-PAGE SDS polyacrylamide gel electrophoresis
  • the proteins are then transferred or electro-blotted onto a membrane, where they are probed and ultimately detected using antibodies specific to a target protein.
  • Western blotting membranes are typically made of nitrocellulose (NC) or polyvinylidene fluoride (PVDF). The specificity of the antibody-antigen interaction can enable a single protein to be identified among a complex protein mixture.
  • NC nitrocellulose
  • PVDF polyvinylidene fluoride
  • Western blotting involves application of a protein sample (lysate) onto a polyacrylamide gel, subsequent separation of said complex mixture by electrophoresis, and transferal or "electro-blotting" of separated proteins onto a second matrix, generally a nitrocellulose or polyvinylidene fluoride (PVDF) membrane. Following the transfer, the membrane is "blocked” to prevent nonspecific binding of antibodies to the membrane surface.
  • a second matrix generally a nitrocellulose or polyvinylidene fluoride (PVDF) membrane.
  • PVDF polyvinylidene fluoride
  • Many antibody labeling or tagging strategies are known to those skilled in the art.
  • the transferred proteins are incubated or complexed with a primary enzyme-labeled antibody that serves as a probe.
  • a suitable substrate is added to complex with the enzyme, and together they react to form chromogenic, chemiluminescent, or fluorogenic detectable products that allow for visual, chemiluminescence, or fluorescence detection, respectively.
  • the most sensitive detection schemes make use of chemiluminescent or fluorescent phenomena.
  • chemiluminescent detection an enzyme-substrate complex produces detectable optical emissions (chemiluminescence). These emissions are recorded and measured using suitable detectors such as film or photonic devices. Absence or presence of signal indicates whether a specific protein is present in the lysate, and signal intensity is related to the level of the protein of interest, which in some cases may be quantifiable.
  • Nitrocellulose blotting membranes do not require an organic liquid pre-wet step, a requirement for working with hydrophobic membranes.
  • Hydrophobic membranes require an alcohol pre-wet step followed by a water exchange step (for alcohol removal), before assembly within the blot-transfer assembly.
  • Intrinsically hydrophobic membranes afford a limited time-frame for this assembly; the potential for the membrane to dry out is significant. Once dry, the membrane cannot be re-wet unless the pre-wet sequence is repeated. Once the membrane is contacted to the gel, removal prior to transfer can effectively ruin the gel and the separated protein samples contained.
  • the pre-wet step is time consuming and can considerably impede workflow.
  • a hydrophilic membrane will remain wet for a longer time interval, and can be re-wet with water if it does dry out before assembly.
  • Nitrocellulose blotting membranes are water wet-able and show satisfactory performance for most blotting applications. But nitrocellulose is not as mechanically or chemically stable as PVDF. PVDF will maintain its mechanical integrity over a long timeframe, whereas NC will become brittle and discolored. PVDF membrane blots can be stripped of antibodies and be re-probed. NC blots cannot. NC is prone to air oxidation, wherein it can become hazardous. It requires a separate waste stream, and when disposed of must be damped with a wetting agent, usually water.
  • Hydrophobic PVDF blotting membranes possess equivalent protein binding ability to NC blotting membranes, but exhibit superior blotting performance. Much lower sample concentrations can be detected under the same conditions on these PVDF membranes compared to NC. Low-background fluorescence hydrophobic PVDF blotting membranes exhibit the same enhanced sample detection while enabling the use of fluorescent detection schemes.
  • hydrophilic PVDF membrane for immunodetection assays such as Western blotting, with performance characteristics that approach the lower sample detection limits and low background fluorescence that are characteristic of hydrophobic PVDF membranes. This invention addresses these requirements.
  • hydrophilic surface modifications traditionally exhibit low protein binding behavior.
  • the embodiments disclosed herein build on the serendipitous and unexpected discovery that space polymers derived from certain monomeric acrylamide mixtures, and formed using free-radical polymerization reactions, can give rise to surface modifications that are not only hydrophilic, but also demonstrate a high level of protein binding.
  • hydroxyl containing monomers usually carbonyl ester containing acrylate polymers
  • polymers from such monomers are not resistant to strong alkaline solutions.
  • a solution of 1.0 normal sodium hydroxide will hydrolyze the carbonyl containing acrylate polymers to acrylic acid containing polymers.
  • acrylic acid containing polymers are ionically charged under certain pH conditions, and will attract and bind oppositely charged proteins or biomolecules, thus increasing sorption and membrane fouling.
  • acrylic acid containing polymers swell in water to an extent that they constrict pore passages, thus reducing membrane permeability and productivity.
  • polymers from hydroxyl containing monomers, such as hydroxy acrylates further react in strong alkaline solutions and degrade into soluble low molecular weight fragments, which dissolve away and expose the underlying substrate porous media or membrane.
  • initial starting levels of each monomer had to be severely decreased before observing satisfactory dot blot morphology and blotting transfer performance.
  • a hydrophilic membrane particularly suited for blotting applications preferably Western blotting. More specifically, a pre-wet hydrophobic membrane substrate, preferably made of PVDF, is contacted with a monomer solution and subjected to polymerizing conditions to render the substrate permanently hydrophilic.
  • the resulting membrane exhibits low background fluorescence, high protein binding, excellent retention of protein sample spot morphology, and extended dynamic range (high signal-to-noise ratio, enhanced sample detectability). Where chemiluminescence is used for detection, the level of background fluorescence inherent in the unmodified parent membrane is not as critical.
  • the membrane demonstrates comparable or higher performance in Western blotting applications than conventional nitrocellulose blotting membranes, particularly for detection at low sample concentrations, and is directly water-wettable, eliminating the need for an alcohol pre-wet step prior to use.
  • the membrane exhibits complete, instant, and uniform wetting upon contact with water, and exhibits delayed wetting when contacted with a saturated aqueous aluminum chloride solution. That is, when said membrane is placed on the surface of this saturated aqueous aluminum chloride solution, it wets through in a minimum time interval of not less than 1 second).
  • the membranes hydrophilically modified in accordance with embodiments of the present disclosure provide immunodetection assay platforms that are comparable to, or exhibit superior blotting performance to nitrocellulose membranes, particularly with respect to expansion of the low end of the dynamic range of sample detectability.
  • FIG. 1 Western blotting results from a typical development run demonstrate the performance differences between the hydrophilic PVDF blotting membrane of this invention, and the controls (FL - hydrophobic PVDF membrane, and NC - Whatman/S&S BA-85 membrane).
  • Each horizontal strip in the figure contains 5 separate Western transfer blots; three blots on hydrophilic PVDF development samples, and one blot on each of the control membranes.
  • Each horizontal strip of 5 Western blots is the result from one electrophoresis and transfer experiment (5 gels followed by 5 blots were run in each experiment).
  • each experiment embodies identical conditions on each gel/blot with identical quantities of protein sample (applied in 4 lanes across each gel) before electrophoresis and transfer.
  • the results shown are the recorded (chemiluminescent) transfer blots for the detection of 2 proteins (HSP70 and GAPDH) from a complex sample mixture (lysate), applied at decreasing sample concentrations, from left-to-right on each gel, and corresponding to: 5 ug, 2.5 ug, 1.25 ug, 0.67 ug.
  • Suitable porous membranes include those formed from aromatic sulfone polymers, polytetrafluoroethylene, perfluorinated thermoplastic polymers, polyolefin polymers, ultrahigh molecular weight polyethylene, polyamides including Nylon 6 and Nylon 66, and polyvinylidene fluoride, with polyvinylidene fluoride being particularly preferred.
  • Porous membranes include both microporous membranes and ultrafiltration membranes, and are preferably in the form of sheets. Generally the average pore sizes include those between 0.001 and 10 microns.
  • Blotting membranes are nominally 0.45um pore size materials. Preferred starting membranes have a porosity (void volume) range specification of 68-73%. Blotting membranes are traditionally symmetric. However, the coating could be applied to an asymmetric membrane.
  • the polymeric coating can be a copolymer or terpolymer formed from at least one polyfunctional monomer modified with at least one hydrophilic functional group, said hydrophilic polyfunctional monomer(s) selected from the group consisting of polyfunctional acrylamides, polyfunctional methacrylamides and diacroylpiperazines, and formed from at least one monofunctional monomer modified with at least one hydrophilic functional group, said hydrophilic monofunctional monomer(s) selected from the group consisting of monofunctional acrylamides, monofunctional methacrylamides, and acryloyl piperazines.
  • a porous hydrophobic membrane preferably one made of polyvinylidene fluoride coated with a crosslinked acrylamide - methylene-bis-acrylamide copolymer was rendered highly hydrophilic.
  • IgG binding assays revealed protein binding levels to be in the neighborhood of 400ug/cm 2 . This level is typical of the parent hydrophobic PVDF membrane and of conventional nitrocellulose membranes. The first surprising result was that membranes so prepared were both hydrophilic, and high protein-binding.
  • component levels and relative concentrations of the modifying formulation are critical to obtain acceptable immunodetection assay performance.
  • a low overall solids concentration in a highly specific component ratio balances water-wetting performance against blotting performance.
  • the very low background fluorescence level of the substrate membrane is preserved. If, however, the level of surface modification chemistry is too low, the result is a membrane that is not water-wettable to an acceptable extent. If the level of surface modification is too high the resulting membranes exhibit extremely high surface energies. As stated earlier, at higher levels of surface modifying chemistry, the measured protein binding capacity is roughly equivalent to nitrocellulose and hydrophobic PVDF membranes, but poor electro-blotting performance results.
  • the total solids level in the modifying/reactant solution is to be adjusted to between 0.90% and 1.10% by weight.
  • a total solids concentration in this range with the specified component ratio results in optimal blotting performance.
  • This formulation includes a UV-photoinitiator component.
  • Suitable amounts of the acrylamide monofunctional monomer and the bis-acrylamide crosslinking monomer in the reactant solution are to be between 0.20% and 2.00% by weight (each), preferably with amounts between 0.30% and 0.60% by weight (each), and most preferably between 0.40% and 0.50% by weight (inclusive, each).
  • the preferred ratio of acrylamide to bis-acrylamide of the monomer reactant solution is about 1:1 (mass/mass).
  • the preferred overall monomer concentration of acrylamide:methylene-bis-acrylamide monomer reactant solution is between 0.5% and 1.5% by mass.
  • a suitable UV-photoinitiator component is present in 0.01% to 0.20% by weight preferably between 0.05 and 0.15% by weight, and most preferably between 0.09% and 0.11%, by weight.
  • Suitable UV-photoinitiators include Irgacure 500, 754, 2959, and 819DW.
  • Methods for preparation of the modified porous membrane substrate in accordance with certain embodiments include the steps of providing a porous membrane substrate, contacting the surface of the porous membrane substrate with a reactant solution comprising acrylamide and methylene-bis-acrylamide, and a suitable photoinitiator, removing the membrane from the solution, and polymerizing the coating in situ on the membrane substrate by exposing the same to radiation of a suitable wavelength and intensity for a suitable time interval.
  • the porous membrane contacted with the reaction solution is irradiated with an ultraviolet light source.
  • Filters may be used to reduce or eliminate undesirable wavelengths which may cause damage to the porous membrane.
  • the amount of exposure time to the UV light and the intensity thereof should be familiar to those skilled in the art.
  • the porous hydrophobic starting membrane is pre-wet by immersion in an organic liquid or in an aqueous solution thereof that does not swell or dissolve the porous membrane, and which pre-wets the entire porous surface of the membrane.
  • the liquid may be a low molecular weight alcohol, or a mixture of water and a miscible organic liquid.
  • Suitable liquids or compositions include methanol, ethanol, isopropanol, water mixtures thereof, acetone/water mixtures, and tetrahydrofuran/water mixtures of sufficiently low surface tension to affect wetting the entire membrane surface.
  • this pre-wetting step is to assure that the entire membrane surface is rendered wettable by water, and subsequently by the aqueous reactant monomer solution.
  • the pre-wetting step must be followed by a rigorous exchange step with water to eliminate the presence of the organic solvent. These pre-wetting solvents or water mixtures thereof can exert a negative influence upon the intended polymerization of the reactant monomers.
  • the sample is withdrawn after a short (two minute) time interval and excess reactant solution is removed from the membrane sample.
  • the reactant solution-wetted membrane is anaerobically exposed to UV radiation to effect the polymerization directly onto the entire porous membrane surface.
  • the resulting coated membrane exhibits: Immediate, complete, and thoroughly uniform wetting when contacted onto a water surface; A high level of Western blotting performance; A high level of protein binding ( ⁇ 250 ug/cm 2 IgG) by radio-labeled assay; and, Low background fluorescence (about 2000 rfu @ 485nm/535nm excitation/emission wavelengths using a TECAN GENios FL fluorescence reader with detector gain set at 86, and running Magellan 5.0 software package), which is about twice the background fluorescence of the untreated (unmodified parent hydrophobic) membrane under the same measurement conditions.
  • the membrane When placed on the surface of a saturated aqueous aluminum chloride solution, the membrane will wet through in
  • Extractable Monomer Levels by HPLC Same samples as shown in Table 1.
  • Example 1 The procedure of Example 1 was used to treat PVDF membranes having the specifications, treatment conditions and reactant solutions shown in Tables 3A-D, 4A-D, and 5A-D.
  • Table 3A MODIFICATION DATA for Hydrophilic PVDF Western Blotting Membrane Membrane Starting Membrane Properties Monomer Starting Casting Roll No.
  • NA NA NA NA NA NA 1275 2 R09 120 71.0 9.5 63.0 Not Taken NA NA NA NA 1375 2 R10 120 71.0 9.5 63.0 Not Taken NA NA NA 1675 3 R11 118 66.7 8.3 46.7 MM4 0.48 0.38 0.09 0.96 1775 3 R12 116 72.3 9.0 56.0 Not Taken NA NA NA NA 1875 3 R13 119 72.4 9.7 66.0 Not Taken NA NA NA NA 1975 3 R14 130 74.7 10.7 74.0 Not Taken NA NA NA NA NA NA NA NA NA 1975 3 R14 130 74.7 10.7 74.0 Not Taken NA NA NA NA NA NA NA NA 2075 3 R15 134 73.4 9.9 65.0 Not Taken NA NA NA NA NA 2175 3 R16 114 72.4.
  • N/Avail. ⁇ NC 3 R15 Y Y Y N (HIGH) N (White) 180 180 180 180 N/Avail. N/Avail. ⁇ NC 3 R16 Y Y Y N (HIGH) Y 180 57.3 16.4 180 N/Avail. N/Avall. ⁇ NC 3 R17 Y Y Y Y 19.3 40.8 5.1 21:7 N/Avail. N/Avail. ⁇ NC 3 NA NA NA NA NA NA NA NA NA NA NA NA NA NA Segment 1 Diagnostic Segment 2 Dryer Temperature & Linespeed Variation Segment 3 Porosity and Thickness Variation - Starting Membrane
  • the results shown are the transfer blots for the detection of 2 proteins (HSP70 and GAPDH) from a complex sample mixture (lysate), applied at decreasing sample solids (concentrations), from left-to-right and corresponding to: 5 ug, 2.5 ug, 1.25 ug, 0.67 ug.
  • the parent application is directed to a porous membrane comprising a polymeric substrate membrane, said polymeric substrate membrane having its surface modified with a crosslinked polymeric coating comprising acrylamide and methylene-bis-acrylamide, wherein said coating renders said surface hydrophilic, and wherein said surface has a protein binding capacity as measured by an IgG binding test of about 250-325 ⁇ g/cm 2 .
  • the average total organic carbon level of said membrane is below 1.5 ⁇ g/cm 2 and/or extractable monomer levels, as determined by HPLC, are below 0.02 ⁇ g/cm 2 for acrylamide, and below 0.15 ⁇ g/cm 2 for methylene-bis-acrylamide.
  • the substrate may have a background fluorescence value, and wherein said modified membrane exhibits a background fluorescence of about twice that of said substrate background fluorescence value under identical measurement conditions.
  • the membrane substrate comprises polyvinylidene fluoride.
  • the ratio of acrylamide to methylene-bis-acrylamide of the monomer reactant solution may be about 1:1 (mass/mass).
  • the overall monomer concentration of the acrylamide : methylene-bis-acrylamide monomer reactant solution may be between 0.5% and 1.5% by mass.
  • the porous membrane may have a photoinitiator level between 0.01 % and 0.20%.
  • the parent application is also directed to a method for preparing a hydrophilic, low background fluorescence, high protein-binding porous membrane comprising a hydrophobic, low background fluorescence, high protein binding porous membrane substrate, and a low background fluorescence surface modification, the method comprising:
  • the amounts of acrylamide and methylene-bis-acrylamide in the reaction solution may be between 0.20% and 2.00%, such as about 0.50% and about 0.40%, respectively.
  • the amount of the photoinitiator in the reaction solution may be between 0.01 % and 0.20%, such as about 0.10%.
  • the photoinitiator may be Irgacure 2959.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Manufacturing & Machinery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Peptides Or Proteins (AREA)
  • Laminated Bodies (AREA)
EP10190559.4A 2008-08-18 2009-08-17 Western-Blot Immunoassay utilisant Membrane à transfert de protéines hydrophile, à liaison à protéines, à faible fluorescence Active EP2302386B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18930208P 2008-08-18 2008-08-18
EP09168000A EP2157430B1 (fr) 2008-08-18 2009-08-17 Membrane à transfert de protéines hydrophile, à liaison à protéines, à faible fluorescence

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP09168000A Division EP2157430B1 (fr) 2008-08-18 2009-08-17 Membrane à transfert de protéines hydrophile, à liaison à protéines, à faible fluorescence
EP09168000.9 Division 2009-08-17

Publications (2)

Publication Number Publication Date
EP2302386A1 true EP2302386A1 (fr) 2011-03-30
EP2302386B1 EP2302386B1 (fr) 2014-04-09

Family

ID=41228326

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09168000A Active EP2157430B1 (fr) 2008-08-18 2009-08-17 Membrane à transfert de protéines hydrophile, à liaison à protéines, à faible fluorescence
EP10190559.4A Active EP2302386B1 (fr) 2008-08-18 2009-08-17 Western-Blot Immunoassay utilisant Membrane à transfert de protéines hydrophile, à liaison à protéines, à faible fluorescence

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09168000A Active EP2157430B1 (fr) 2008-08-18 2009-08-17 Membrane à transfert de protéines hydrophile, à liaison à protéines, à faible fluorescence

Country Status (6)

Country Link
US (2) US8132676B2 (fr)
EP (2) EP2157430B1 (fr)
JP (2) JP5254903B2 (fr)
CN (2) CN103364565B (fr)
ES (2) ES2397680T3 (fr)
SG (2) SG159461A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0509422D0 (en) * 2005-05-09 2005-06-15 Mabtech Ab Membranes
EP2484431B1 (fr) * 2009-09-30 2017-06-07 Amomedi Co., Ltd. Membrane à base de nanofibres pour transfert de western et son procédé de préparation
US9689042B2 (en) 2012-09-07 2017-06-27 The Regents Of The University Of California Use of glycolytic pathways for inhibiting or measuring oncogenic signaling
CN103418256B (zh) * 2013-05-27 2015-08-05 镇江高鹏药业有限公司 一种对羟基苯甲酸分子印迹膜的合成方法及其应用
CN110054661A (zh) 2013-12-12 2019-07-26 Emd密理博公司 使用含丙烯酰胺的过滤器分离蛋白
TWI518316B (zh) 2014-04-01 2016-01-21 財團法人工業技術研究院 光學測讀系統及使用該系統之生化檢測方法
US9630151B2 (en) * 2015-03-31 2017-04-25 Pall Corporation Hydrophilically modified fluorinated membrane (V)
JP6727322B2 (ja) * 2016-03-18 2020-07-22 インテグリス・インコーポレーテッド ガス抜きプロセス、脱ガスプロセス及び膜蒸留プロセスにおける使用のための疎水性ポリエチレン膜
CN107446569B (zh) * 2017-07-14 2019-09-27 广西师范大学 一种藻蓝蛋白吸附聚偏二氟乙烯荧光膜的制备方法及其应用
CA3099267A1 (fr) * 2018-05-08 2019-11-14 Yale University Membrane de capture de proteine et son procede d'utilisation
CN108841143B (zh) * 2018-05-24 2019-08-27 山东大学 一种Western Blot用微孔薄膜及其制备方法
CN112823856A (zh) * 2019-11-21 2021-05-21 苏州顺创新能源科技有限公司 一种亲水性pvdf薄膜及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0916800A1 (fr) 1997-11-17 1999-05-19 Mauro Pincelli Profilé pour un cadre de porte ou de fenêtre, en particulier pour un ouvrant d'une jalousie à lamelles orientables
WO2002087734A1 (fr) * 2001-04-27 2002-11-07 Millipore Corporation Nouvelles membranes recouvertes et autres articles
WO2003103814A1 (fr) * 2002-06-07 2003-12-18 Millipore Corporation Substrat a membrane microporeuse presentant une surface stable et caustique, a faible affinite pour les proteines,

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3007A (en) * 1843-03-21 Improvement in salt-boilers
US4516845A (en) 1983-10-03 1985-05-14 Polaroid Corporation Security control system and method for identification card cameras
US4618533A (en) * 1984-11-30 1986-10-21 Millipore Corporation Porous membrane having hydrophilic surface and process
US4678813A (en) 1985-11-11 1987-07-07 Mitsubishi Rayon Co., Ltd. Hydrophilized porous polyolefin membrane and production process thereof
US4695592A (en) 1986-01-07 1987-09-22 Mitsubishi Rayon Co., Ltd. Hydrophilized porous membrane and production process thereof
JPS63190602A (ja) * 1986-01-07 1988-08-08 Mitsubishi Rayon Co Ltd 親水化多孔質膜及びその製造方法
US4906374A (en) 1986-12-23 1990-03-06 Pall Corporation Filtration media with low protein adsorbability
US4968533A (en) 1986-12-23 1990-11-06 Pall Corporation Method of preparing membranes with low protein adsorbability
US5019260A (en) 1986-12-23 1991-05-28 Pall Corporation Filtration media with low protein adsorbability
US5322769A (en) * 1988-03-11 1994-06-21 Abbott Laboratories Methods for using CKS fusion proteins
JP2794592B2 (ja) * 1989-05-29 1998-09-10 ハイモ株式会社 生体液中の高分子物質の濃縮方法
US5112736A (en) 1989-06-14 1992-05-12 University Of Utah Dna sequencing using fluorescence background electroblotting membrane
US4944879A (en) 1989-07-27 1990-07-31 Millipore Corporation Membrane having hydrophilic surface
US5336596A (en) * 1991-12-23 1994-08-09 Tropix, Inc. Membrane for chemiluminescent blotting applications
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
RU2111254C1 (ru) * 1994-07-11 1998-05-20 Институт молекулярной биологии им.В.А.Энгельгардта РАН СПОСОБ ДЕТЕКЦИИ ДИФФЕРЕНЦИАЛЬНО ЭКСПРЕССИРУЮЩИХСЯ МАТРИЧНЫХ РНК И КЛОНИРОВАНИЯ СООТВЕТСТВУЮЩИХ ИМ ФРАГМЕНТОВ кДНК
WO1998001208A1 (fr) 1996-07-08 1998-01-15 Memtec America Corporation Membranes cationiques a charge modifiee
US6153596A (en) * 1996-12-18 2000-11-28 Emory University Polycationic oligomers
US5929214A (en) 1997-02-28 1999-07-27 Cornell Research Foundation, Inc. Thermally responsive polymer monoliths
US6013460A (en) * 1997-09-12 2000-01-11 Immunetics, Incorporated Modified western blot membrane and method for detecting lyme disease and other tick-borne diseases
DE69939253D1 (de) * 1998-12-02 2008-09-18 Lg Chemical Ltd Verfahren zur veränderung von polymeroberflächen zur besseren benetzbarkeit
JP2001163932A (ja) * 1999-10-27 2001-06-19 Novartis Ag 材料表面を改質する方法
US6558734B2 (en) 2001-02-09 2003-05-06 Medtronic, Inc. Methods for modifying surfaces of articles
EP1779922B1 (fr) 2001-04-27 2010-06-09 Millipore Corporation Nouvelles membranes revêtues et autres articles
ATE336721T1 (de) * 2002-06-03 2006-09-15 Pamgene Bv Hoch-durchsatz assay zur messung von zellulären antworten mit hilfe von mikroarrays
US6875331B2 (en) * 2002-07-11 2005-04-05 Applied Materials, Inc. Anode isolation by diffusion differentials
JP2005010104A (ja) * 2003-06-20 2005-01-13 Sanei Gen Ffi Inc 製品中のタウマチンの分析方法
JP5042820B2 (ja) * 2004-05-14 2012-10-03 ベクトン・ディキンソン・アンド・カンパニー 生物活性表面を有する物品およびそれらの無溶媒調製法
US7537718B2 (en) 2004-10-13 2009-05-26 3M Innovative Properties Company Hydrophilic polyethersulfone membrane and method for preparing same
CN100337729C (zh) * 2005-10-22 2007-09-19 燕山大学 聚偏氟乙烯微滤分离膜的化学改性方法
US7390729B2 (en) 2006-09-21 2008-06-24 United Microelectronics Corp. Method of fabricating a semiconductor device
GB0619626D0 (en) 2006-10-05 2006-11-15 Ge Healthcare Uk Ltd Fluoro-substituted benzoxazole polymethine dyes
CN1963664A (zh) * 2006-12-07 2007-05-16 河南大学 短波长宽频带光敏感全息记录材料及其制备方法
CN101205305A (zh) * 2007-12-05 2008-06-25 天津工业大学 一种荷负电聚偏氟乙烯改性膜及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0916800A1 (fr) 1997-11-17 1999-05-19 Mauro Pincelli Profilé pour un cadre de porte ou de fenêtre, en particulier pour un ouvrant d'une jalousie à lamelles orientables
WO2002087734A1 (fr) * 2001-04-27 2002-11-07 Millipore Corporation Nouvelles membranes recouvertes et autres articles
WO2003103814A1 (fr) * 2002-06-07 2003-12-18 Millipore Corporation Substrat a membrane microporeuse presentant une surface stable et caustique, a faible affinite pour les proteines,

Also Published As

Publication number Publication date
EP2302386B1 (fr) 2014-04-09
US8132676B2 (en) 2012-03-13
JP2013140183A (ja) 2013-07-18
ES2397680T3 (es) 2013-03-08
JP2010043263A (ja) 2010-02-25
CN101703923B (zh) 2013-06-26
SG159461A1 (en) 2010-03-30
US20100044302A1 (en) 2010-02-25
EP2157430A1 (fr) 2010-02-24
US8143067B2 (en) 2012-03-27
ES2461616T3 (es) 2014-05-20
JP5254903B2 (ja) 2013-08-07
SG190664A1 (en) 2013-06-28
CN101703923A (zh) 2010-05-12
CN103364565B (zh) 2016-09-21
EP2157430B1 (fr) 2012-12-19
CN103364565A (zh) 2013-10-23
US20110045493A1 (en) 2011-02-24
JP5661848B2 (ja) 2015-01-28

Similar Documents

Publication Publication Date Title
EP2302386B1 (fr) Western-Blot Immunoassay utilisant Membrane à transfert de protéines hydrophile, à liaison à protéines, à faible fluorescence
EP1511558B1 (fr) Substrat a membrane microporeuse presentant une surface stable et caustique, a faible affinite pour les proteines,
JP5219231B2 (ja) 新規なコート膜およびその他の製品
AU2004232679A1 (en) Hydrophilic membrane and process for making the same
Amanda et al. Comparison of Protein Fouling on Heat‐Treated Poly (vinyl alcohol), Poly (ether sulfone) and Regenerated Cellulose Membranes Using Diffuse Reflectance Infrared Fourier Transform Spectroscopy
EP0762928B1 (fr) Membranes a fonction azlactone et procedes de preparation et d'utilisation de ces membranes
WO1991002577A1 (fr) Methode de titrage utilisant des membranes activees au polyaldehyde
JP6030751B2 (ja) 乾燥蒸気処理後の試験容易性が向上したフィルタエレメント
EP1779922B1 (fr) Nouvelles membranes revêtues et autres articles

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2157430

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

17P Request for examination filed

Effective date: 20110926

17Q First examination report despatched

Effective date: 20111020

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EMD MILLIPORE CORPORATION

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20130813

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140116

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 2157430

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 661613

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140415

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL AND PARTN, CH

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2461616

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20140520

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009023214

Country of ref document: DE

Effective date: 20140522

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 661613

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140409

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140709

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140809

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140709

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140710

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140811

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009023214

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20150112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140817

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009023214

Country of ref document: DE

Effective date: 20150112

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20090817

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140409

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230602

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230711

Year of fee payment: 15

Ref country code: ES

Payment date: 20230901

Year of fee payment: 15

Ref country code: CH

Payment date: 20230902

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240627

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240613

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240611

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240625

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20240703

Year of fee payment: 16